Clinuvel Pharmaceuticals Stock Performance
| CLVLF Stock | USD 7.70 0.00 0.00% |
The firm shows a Beta (market volatility) of 0.2, which signifies not very significant fluctuations relative to the market. As returns on the market increase, Clinuvel Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Clinuvel Pharmaceuticals is expected to be smaller as well. Clinuvel Pharmaceuticals right now shows a risk of 2.53%. Please confirm Clinuvel Pharmaceuticals maximum drawdown, and the relationship between the jensen alpha and semi variance , to decide if Clinuvel Pharmaceuticals will be following its price patterns.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Clinuvel Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. Despite nearly stable essential indicators, Clinuvel Pharmaceuticals is not utilizing all of its potentials. The current stock price disturbance, may contribute to mid-run losses for the stockholders. ...more
| Begin Period Cash Flow | 82.7 M | |
| Total Cashflows From Investing Activities | -434.4 K | |
| Free Cash Flow | 39.4 M |
Clinuvel |
Clinuvel Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 777.00 in Clinuvel Pharmaceuticals on September 26, 2025 and sell it today you would lose (7.00) from holding Clinuvel Pharmaceuticals or give up 0.9% of portfolio value over 90 days. Clinuvel Pharmaceuticals is currently producing 0.0166% returns and takes up 2.5251% volatility of returns over 90 trading days. Put another way, 22% of traded pink sheets are less volatile than Clinuvel, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Clinuvel Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Clinuvel Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Clinuvel Pharmaceuticals, and traders can use it to determine the average amount a Clinuvel Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0066
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | CLVLF |
Based on monthly moving average Clinuvel Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Clinuvel Pharmaceuticals by adding Clinuvel Pharmaceuticals to a well-diversified portfolio.
Clinuvel Pharmaceuticals Fundamentals Growth
Clinuvel Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Clinuvel Pharmaceuticals, and Clinuvel Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Clinuvel Pink Sheet performance.
| Return On Equity | 0.19 | |||
| Return On Asset | 0.18 | |||
| Profit Margin | 0.32 % | |||
| Operating Margin | 0.54 % | |||
| Current Valuation | 635.56 M | |||
| Shares Outstanding | 49.41 M | |||
| Price To Earning | 34.88 X | |||
| Price To Book | 8.27 X | |||
| Price To Sales | 10.65 X | |||
| Revenue | 65.72 M | |||
| EBITDA | 37.35 M | |||
| Cash And Equivalents | 121.51 M | |||
| Cash Per Share | 2.46 X | |||
| Total Debt | 1.26 M | |||
| Debt To Equity | 0.01 % | |||
| Book Value Per Share | 2.54 X | |||
| Cash Flow From Operations | 39.87 M | |||
| Earnings Per Share | 0.28 X | |||
| Total Asset | 143.95 M | |||
| Retained Earnings | (133 M) | |||
| Current Asset | 20 M | |||
| Current Liabilities | 2 M | |||
About Clinuvel Pharmaceuticals Performance
By analyzing Clinuvel Pharmaceuticals' fundamental ratios, stakeholders can gain valuable insights into Clinuvel Pharmaceuticals' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Clinuvel Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Clinuvel Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. The company was founded in 1987 and is headquartered in Melbourne, Australia. Clinuvel Pharm operates under Biotechnology classification in the United States and is traded on OTC Exchange.Things to note about Clinuvel Pharmaceuticals performance evaluation
Checking the ongoing alerts about Clinuvel Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Clinuvel Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| About 21.0% of the company shares are held by company insiders |
- Analyzing Clinuvel Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Clinuvel Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Clinuvel Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Clinuvel Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Clinuvel Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Clinuvel Pharmaceuticals' pink sheet. These opinions can provide insight into Clinuvel Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Clinuvel Pink Sheet analysis
When running Clinuvel Pharmaceuticals' price analysis, check to measure Clinuvel Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Clinuvel Pharmaceuticals is operating at the current time. Most of Clinuvel Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Clinuvel Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Clinuvel Pharmaceuticals' price. Additionally, you may evaluate how the addition of Clinuvel Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios |